Lombardi C, Gargioni S, Canonica G W, Passalacqua G
Pneumoallergology Unit, Sant'Orsola FBF Hospital, Brescia.
Eur Ann Allergy Clin Immunol. 2008 Dec;40(4):138-41.
Nocebo effect is the occurrence of troublesome symptoms after the administration of inert substances. It can be easily studied during blind oral challenges for drug reactions, which always involve the administration ofa placebo.
We collected data about nocebo effect in outpatients undergoing oral drug challenge. Patients with previous documented adverse reactions to drugs underwent an oral challenge with alternative drugs to identify the compounds that can be safely used The challenges involved the administration of aplacebo before the active drugs and were performed under medical supervision.
Four hundred and thirty-five patients (18-68 yrs, 68% female) underwent the oral drug challenge. Most of them (52%) had a previous reaction with antibiotics and non-steroidal antinflammatory drugs. The reported reactions were urticaria (and/or angioedema), respiratory complaints, generalized itching and non-specific symptoms. A nocebo effect was seen in 13patients (3%), (10 female). The majority of the observed effects were subjective (malaise, itching, abdominal pain). No special demographic or clinical characteristic could be identified in the nocebo reactors. Ten/13 patients had an abnormal result at the hospital anxiety depression questionnaire.
Nocebo effect was not negligible in this procedure, although lessfrequent than previously reported.
反安慰剂效应是指在给予惰性物质后出现不良症状。在药物反应的盲法口服激发试验中很容易对其进行研究,这类试验总是涉及给予安慰剂。
我们收集了接受口服药物激发试验的门诊患者的反安慰剂效应数据。既往有药物不良反应记录的患者接受替代药物的口服激发试验,以确定可以安全使用的化合物。激发试验在给予活性药物之前先给予安慰剂,并在医疗监督下进行。
435例患者(年龄18 - 68岁,68%为女性)接受了口服药物激发试验。其中大多数(52%)既往对抗生素和非甾体抗炎药有反应。报告的反应包括荨麻疹(和/或血管性水肿)、呼吸道症状、全身性瘙痒和非特异性症状。13例患者(3%,10例女性)出现了反安慰剂效应。观察到的效应大多是主观的(不适、瘙痒、腹痛)。在出现反安慰剂效应的患者中未发现特殊的人口统计学或临床特征。13例患者中有10例在医院焦虑抑郁问卷上结果异常。
在该过程中反安慰剂效应不可忽视,尽管其发生率低于先前报道。